Is it worth it?
The real question that should be asked about the possible Dexcom acquisition of Insulet is it really worth it? Now it’s obvious that Insulet and their stakeholders would be big winners here. Dexcom would likely pay a 15% premium to acquire Insulet which would require some serious dilution to Dexcom stakeholders, and we’d imagine another 20% or so chopped off the stock price. So just what exactly does Dexcom get? Or maybe we should ask this a different way what are they getting that they don’t already have?
We realize when so much money is . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.